Surfing the MASH Tsunami

What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25

September 09, 2020 HEP Dynamics LLC Season 1 Episode 25
Surfing the MASH Tsunami
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
Show Notes

The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.

The Surfers considered the implication of a Digital ILC presentation by James Paik et al. titled "Causes of death in patients with non-alcoholic fatty liver disease (NAFLD): data from national vital statistics system (NVSS)." The presentation demonstrated that liver disease, not cardiovascular, is the leading cause of death for NAFLD patients, with broad implications for treating early-stage patients. Surfers asked: If NAFLD patients "feel bad" all the time, can patient-reported outcomes become a primary measure? Shouldn't metabolic measures remain vitally important for patients most of whom are obese and exhibit concomitant Type 2 diabetes or cardiovascular disease? And which test(s) provide the greatest support for FibroScan in demonstrating positive predictive value? A tremendous amount of content and tips from Dr. Harrison and Prof. Schattenberg. You'll want to listen more than once!